ReviewAntibiotics (Basel, Switzerland)2022
Current Promising Strategies against Antibiotic-Resistant Bacterial Infections.
Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Nanotechnology-Enabled Strategies to Overcome Antibiotic Resistance in Respiratory Infections: Mechanisms, Platforms, and Translational Challenges.Biomedicines · 2026Review
- Herbal extracts as antibiotic adjuvants against ESKAPE pathogens: mechanisms and therapeutic potential.Engineering microbiology · 2026Review
- In vitro antibacterial activity and in silico validation of phytocompound Emodin from Rheum Emodi Wall. Ex Meissn. against Staphylococcus aureus and Enterobacter cloacae.World journal of microbiology & biotechnology · 2026Article
- Antibody-Antibiotic Conjugates: Mechanisms, Clinical Progress, and Next-Generation Strategies Against Multidrug-Resistant Bacterial Infections.MicrobiologyOpen · 2026Review
- Bacterial quorum-sensing systems in cell-cell communication.FEMS microbiology reviews · 2026Review
- Chitosan-coated silver nanoparticles amplify glycopeptide efficacy againstFrontiers in microbiology · 2026Article
- Article
- Assessment of MgO, ZnO, chitosan hydroxyapatite and silver hydroxyapatite nanoparticles against carbapenem-resistant Gram-negative Egyptian clinical isolates: a combined in-silico and in-vitro study.BMC microbiology · 2025Article
- Profile of predominant gram-negative pathogenic bacteria in River Sosiani and wastewater systems in Eldoret Town, Uasin Gishu County, Kenya.Microbiology spectrum · 2025Article
- Novel Antibacterial Approaches and Therapeutic Strategies.Antibiotics (Basel, Switzerland) · 2025Review
- Photodynamic Inactivation ofBiomacromolecules · 2025Article
- Impact of nafcillin and diosmin on the attachment, invasion, and stress survival of Salmonella Typhimurium.Scientific reports · 2025Article
- Article
- Identification of metabolic pathways modulated by GAM and NGAM in the inhibition ofFrontiers in microbiology · 2025Article
- A Screen of Traditional Chinese Medicinal Plant Extracts Reveals 17 Species with Antimicrobial Properties.Antibiotics (Basel, Switzerland) · 2024Article
- Environmental Antimicrobial Resistance: Implications for Food Safety and Public Health.Antibiotics (Basel, Switzerland) · 2024Review
- Conjugated therapeutic proteins as a treatment for bacteria which trigger cancer development.iScience · 2024Review
- Exploring Biosurfactants as Antimicrobial Approaches.Pharmaceuticals (Basel, Switzerland) · 2024Review
- SynthesizedNanomaterials (Basel, Switzerland) · 2024Article
- Review on Long Non-Coding RNAs as Biomarkers and Potentially Therapeutic Targets for Bacterial Infections.Current issues in molecular biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infections caused by antibiotic-resistant bacteria (ARB) are one of the major global health challenges of our time. In addition to developing new antibiotics to combat ARB, sensitizing ARB, or pursuing alternatives to existing antibiotics are promising options to counter antibiotic resistance. This review compiles the most promising anti-ARB strategies currently under development. These strategies include the following: (i) discovery of novel antibiotics by modification of existing antibiotics, screening of small-molecule libraries, or exploration of peculiar places; (ii) improvement in the efficacy of existing antibiotics through metabolic stimulation or by loading a novel, more efficient delivery systems; (iii) development of alternatives to conventional antibiotics such as bacteriophages and their encoded endolysins, anti-biofilm drugs, probiotics, nanomaterials, vaccines, and antibody therapies. Clinical or preclinical studies show that these treatments possess great potential against ARB. Some anti-ARB products are expected to become commercially available in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.